Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Madhu Dhar has a total of 280 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From lignin to living systems: Carbon dots modulate early cytoskeletal organization and phenotypic marker expression in undifferentiated mesenchymal stem cells

    by Eli Christoph, Emine Berfu Ozmen, Isaac Cutshall, Nikolaos Zaharas, Jonah Brown, Steven D. Newby, David P. Harper, Madhu Dhar

  • Open Access

    Material-Driven Therapeutics to Establish a Penetrating Traumatic Brain Injury Rat Model and Implantation of a 3D-Printed Scaffold: Pre-Experimental Pilot Study

    by Meaghan E Harley-Troxell, Michelle Dennis, Madhu Dhar

    Background: Traumatic brain injuries (TBIs) are a leading cause of death and disability, with penetrating TBIs the most lethal form. While no TBI treatments currently exist, ongoing investigations are developing biomaterial scaffolds and cellular therapies to improve the poor outcomes of this disease. Objective: This pilot study established a TBI rat model that maintains focal damage to the cerebral cortex while manually disrupting the blood-brain barrier (BBB). BBB-disrupting injuries require different management from others, allowing us to develop a specific, therapeutic treatment for this type of injury. We hypothesized that our method of BBB disruption would indicate behavioral, physical, and histological evidence of a TBI. Our TBI model will also create a cranial opening in which we can ensure surgical feasibility of implantation of a scaffold. We hypothesized that the implantation of a Food and Drug Administration–approved synthetic polymer, poly(lactic-co-glycolic) acid (PLGA), and a carbon-based nanomaterial, reduced graphene oxide (rGO), would not show evidence of foreign body rejection 30 days after surgery. Methods: Sprague Dawley rats (N=4) underwent stereotaxic surgery with a 5-mm craniotomy. The dura and brain tissue were disrupted using a beaver blade. The PLGA/rGO scaffold was gently placed onto the brain tissue. Neurological function (including body condition, breathing, spontaneous behavior, handling reaction) was evaluated for the first 3 days, then weekly throughout the 30-day study. At 30 days, the brains were dissected, paraffin embedded, and sectioned for H&E and Prussian blue staining, and immunohistochemistry (IHC) using glial fibrillary acidic protein, neuronal nuclei (NeuN), von Willebrand factor, neurofilament light chain, ionized calcium-binding adapter molecule 1, and CD68 markers. Data were expressed as means and SDs, and 2-tailed t tests were used to determine statistical significance ( P ≤.05). Results: Neurological function assessments indicated no change in rat behavior and normal wound healing over the 30-day study. H&E and Prussian blue staining indicated mild leptomeningeal thickening and evidence of hemosiderin in 3 rats. One rat had foreign body giant cells and an abscess around the implanted material, with evidence of more severe leptomeningeal thickening and hemosiderin. IHC indicated normal anatomic structures with no changes in 5 of the 6 markers 30 days after surgery. NeuN significantly decreased in expression, from 9.65% to 4.56% in area, for all 4 rats ( P =.02). Conclusions: While there was no behavioral or symptomatic evidence of TBI, histology showed evidence of mild, focal TBI in 3 of the 4 rats and evidence of a foreign body response and a severe, focal TBI in 1 rat. This pilot study provides a basis for future studies to perform IHC at earlier time points to confirm additional biomarkers. Future studies will also implant a scaffold that is more mechanically aligned with the brain tissue to further evaluate the biocompatibility of graphene nanoparticles in brain tissue and the effectiveness of a therapeutic scaffold.


  • Open Access

    Biomimetic Constructs for Achilles Tendon Regeneration and their Translation to Human Medicine

    by Emine Berfu Ozmen, David E. Anderson, Andrew Ward, Madhu Dhar

    Background: Achilles tendon injuries are among the most common lower-body tendon injuries, often resulting fromoveruse and repetitive motion. Current treatments, ranging from conservative therapies to biological grafts, have drawbacks, including limited regenerative capacity and the risk of graft rejection. To overcome these challenges, tissue engineering shows growing promise for Achilles tendon regeneration, with ongoing research focused on developing biomimetic constructs that utilize various materials and biologics. Since every tendon has unique biomechanical and physiological characteristics, it is crucial to conduct individualized evaluations through detailed research and to address key considerations for clinical translation. Methods: This review focuses explicitly on advances in Achilles tendon tissue engineering for human medicine, assessing constructs made from natural, synthetic, and composite materials with/without biologics and discussing their clinical translation. Studies were searched in the PubMed database and Google Scholar, using the most relevant keywords, such as “Achilles tissue engineering”, “Achilles biomimetic constructs”, “Biomaterials for Achilles tendon”, and “Clinical translation”. Results: Biomimetic constructs developed from various polymers and their combinations, when integrated with stem cells, demonstrate promising potential to reconstruct tissue microenvironments in vitro and to facilitate tissue repair and biomechanical functions in vivo. Carefully developing each element, including appropriate material structures, is essential for optimizing cell responses, biomechanical properties, and tissue repair in the Achilles tendon. Although the in vitro and in vivo advances reviewed in the paper contribute to clinical research, further studies with reproducible, long-term outcomes are needed to make the constructs clinically applicable in human medicine. Conclusion: Achilles tissue engineering continues to progress, driven by a deeper understanding of the injuries and the integration of regenerative tools. Furthermore, clinical considerations, such as long-term in vivo follow-up to assess biocompatibility and functional recovery, will be critical to achieving clinical outcomes.


  • Open Access

    Investigation of peripheral rat blood immune phenotype to evaluate the biocompatibility of graphene nanoparticles and xenografted mesenchymal stem cells

    by Meaghan E. Harley-Troxell, Mohamed A. Abouelkhair, Steven D. Newby, Briana Lewis, David E. Anderson, Madhu Dhar

    Aim: Peripheral nerve injuries (PNIs) often result in a diminished quality of life for those affected and are the most common nervous system injury, with limited treatment options. Regenerative medicine presents novel biomaterial and cell-based therapies to repair the damaged tissue. Graphene oxide (GO), and mesenchymal stem cells (MSCs) have the potential to serve as components to treat PNI. This study evaluates the systemic toxicity of GO and xenogenic human MSCs by analyzing the peripheral blood immune phenotype when a novel nerve guidance conduit (NGC) is implanted in a rat model for six months. Methods: A 10-mm long sciatic nerve defect model was created in 8–10-week-old Lewis rats. Four treatment groups were generated: autograft (positive control), poly (lactic-co-glycolic acid) (PLGA) NGC, PLGA NGC with 0.25% GO, and PLGA/GO NGC seeded with 1 × 106 human adipose-derived MSCs. Tail blood was collected before surgery, and at 24 hours, 2 weeks, 2, 3, 5, and 6 months after surgery. Hematological analyses were carried out to evaluate systemic changes, if any, in peripheral immune cell types, namely, T lymphocytes, B lymphocytes, natural killer cells, and macrophages. The treated and contralateral sciatic nerves were excised, paraffin embedded, sectioned, and H&E stained, to identify any local foreign body rejection. Results: Treatment groups with GO and MSCs displayed percent total values of peripheral immune cells equivalent to the autograft at each time point. There was no evidence of an inflammatory response in the histological samples. Conclusions: The lack of changes in immune phenotype demonstrates a lack of nanotoxicity of the graphene nanoparticles and no evidence of adverse effects due to the MSCs. This was further supported by a lack of local foreign body response at the site of implantation. Overall, the PLGA/GO NGC + MSCs construct is biocompatible for six months in a rat PNI model, exhibiting a potential for clinical translation.

  • Open Access

    A Pilot Study to Establish a Penetrating Traumatic Brain Injury Rat Model for Implantation of a 3D Printed Scaffold

    by Meaghan E. Harley-Troxell, Michelle Dennis, Madhu S. Dhar

    Introduction: Traumatic brain injuries (TBIs) are the leading cause of death and disability, with penetrating TBIs being the most lethal form. As the primary injury involves a foreign object breaking the skull, disrupting the blood brain barrier (BBB), and damaging the brain tissue, the secondary injury that follows is further damaging with persistent inflammation leading to tissue atrophy. While no TBI treatments currently exist, ongoing investigations are developing biomaterial scaffolds and cellular therapies to improve upon the poor outcomes from this disease. This pilot study sets out to establish a TBI rat model that maintains focal damage to the cerebral cortex, while manually disrupting the BBB. Injuries disrupting this barrier need to be managed differently than those that do not, allowing us to develop a specific, therapeutic treatment for this type of injury. We hypothesize that our method of BBB disruption will indicate behavioral, physical, and histological evidence of a TBI. Our TBI model will also create a cranial opening in which we can ensure surgical feasibility of implantation of a scaffold. We hypothesize the implantation of FDA-approved synthetic polymer, poly (lactic-co-glycolic acid) (PLGA), and carbon-based nanomaterial, reduced graphene oxide (rGO), will not show evidence of a foreign body rejection at 30 days after surgery. Methods: Four Sprague Dawley rats underwent a stereotaxic surgery with a 5-mm craniotomy. The dura and brain tissue were disrupted using a beaver blade. The PLGA/rGO scaffold was gently placed onto the brain tissue. Neurological function was evaluated for the first three days, then weekly throughout the 30-day study. At 30 days, brains were dissected, paraffin embedded, and sectioned for H&E and Prussian blue staining, and immunohistochemistry (IHC). Results: Neurological function assessments indicated no change in rat behavior and normal wound healing over the 30 day study. H&E and Prussian blue staining indicated mild leptomeningeal thickening and evidence of hemosiderin in 3 rats. One rat had foreign body giant cells and an abscess around the implanted material with evidence of more severe leptomeningeal thickening and hemosiderin. IHC indicated normal anatomic structures with no changes in 5 of the 6 markers at 30 days after surgery. Neural marker, NeuN, had a significant decrease in expression for all four rats. Discussion: While there was no behavioral or symptomatic evidence of a TBI, histology showed evidence of a mild, focal TBI in 3 of the 4 rats, and evidence of a foreign body response and a severe, focal TBI in 1 rat. Future studies will perform IHC at earlier timepoints to confirm additional biomarkers, and will implant a scaffold that is more mechanically aligned with the brain tissue to further evaluate the biocompatibility of graphene nanoparticles in brain tissue, and the effectiveness of a therapeutic scaffold.


  • Open Access

    3D-Printed Poly (Lactic-Co-Glycolic Acid) and Graphene Oxide Nerve Guidance Conduit with Mesenchymal Stem Cells for Effective Axon Regeneration in a Rat Sciatic Nerve Defect Model

    by Meaghan Harley-Troxell, Alisha P Pedersen, Steven D Newby, Eli Christoph, Stacy Stephenson, Thomas J Masi, Dustin L Crouch, David Anderson, Madhu Dhar

    Introduction: Peripheral nerve injuries (PNIs) impact the quality of life of millions of people. The current gold standard of treatment, the autograft, fails to restore nerve function and is often associated with untoward effects. The alternative interventions available remain unable to ensure full functional recovery. For this study we developed a 3D printed nerve guidance conduit (NGC) composed of poly (lactic-co-glycolic acid) (PLGA) and 0.25% graphene oxide (GO), that can be seeded with human adipose-derived mesenchymal stem cells (MSCs), to develop a more effective treatment for PNI. Methods: We evaluated material degradation, surface topography, and MSC attachment in vitro. For the in vivo analyses, a 10-mm long sciatic nerve defect model was created, and rats were randomly divided into 4 treatment groups: autograft, PLGA, PLGA/GO, and PLGA/GO with 1× 106 MSCs. For a 6-month period: biomechanics were evaluated using a pressure mat walkway to determine functional repair; systemic toxicity was evaluated using transmission electron microscopy of kidney and lung tissue; immunohistochemistry evaluated local adverse effects, myelin sheath and axonal repair; and gross muscle analyses of the lateral gastrocnemius, medial gastrocnemius, and soleus evaluated muscle reinnervation. Results: In vitro results showed expected degradation rates, and the addition of GO exhibited cytocompatibility and favorable cell attachment. In vivo results showed biocompatibility with no translocation of the graphene nanoparticles. Histology showed evidence of axonal and myelin sheath repair. Biomechanics and gross muscle analyses had contradicting evidence of functional repair with the addition of GO. No differences were seen with the addition of MSCs. Conclusion: Our novel PLGA/GO NGC, both with and without MSCs, showed results comparable to or greater than the current gold standard, as well as ease of use surgically. With further studies to validate functional recovery, this specific combination of PLGA and GO may provide an effective biomimetic therapy to repair PNIs.


  • Open Access

    Isolation and Characterization of Canine Adipose-Derived Mesenchymal Stromal Cells: Considerations in Translation from Laboratory to Clinic

    by Michael A. Rivera Orsini, Emine Berfu Ozmen, Alyssa Miles, Steven D. Newby, Nora Springer, Darryl Millis, Madhu Dhar

    In allogeneic MSC implantation, the cells are isolated from a donor different from the recipient. When tested, allogeneic MSCs have several advantages over autologous ones: faster cell growth, sufficient cell concentration, and readily available cells for clinics. To ensure the safe and efficient use of allogeneic MSCs in clinics, the MSCs need to be first tested in vitro. With this study, we paved the way by addressing the in vitro aspects of canine adipose-derived MSCs, considering the limited studies on the clinical use of canine cells. We isolated cAD-MSCs from canine falciform ligament fat and evaluated their viability and proliferation using an MTS assay. Then, we characterized the MSC-specific antigens using immunophenotyping and immunofluorescence and demonstrated their potential for in vitro differentiation. Moreover, we established shipping and cryobanking procedures to lead the study to become an off-the-shelf therapy. During expansion, the cells demonstrated a linear increase in cell numbers, confirming their proliferation quantitatively. The cells showed viability before and after cryopreservation, demonstrating that cell viability can be preserved. From a clinical perspective, the established shipping conditions demonstrated that the cells retain their viability for up to 48 h. This study lays the groundwork for the potential use of allogeneic cAD-MSCs in clinical applications.


  • Open Access

    Electrospun PCL Nerve Wrap Coated with Graphene Oxide Supports Axonal Growth in a Rat Sciatic Nerve Injury Model

    by Meaghan E. Harley-Troxell, Richard Steiner, Steven D. Newby, Austin J. Bow, Thomas J. Masi, Nicholas Millis, Alicia Adina Matavosian, Dustin Crouch, Stacy Stephenson, David E. Anderson, et al.

    Background/Objectives: Peripheral nerve injuries (PNIs) are a debilitating problem, resulting in diminished quality of life due to the continued presence of both chronic and acute pain. The current standard of practice for the repair of PNIs larger than 10 mm is the use of autologous nerve grafts. Autologous nerve grafts have limitations that often result in outcomes that are not sufficient to remove motor and sensory impairments. Bio-mimetic nanocomposite scaffolds combined with mesenchymal stem cells (MSCs) represent a promising approach for PNIs. In this study, we investigated the potential of an electrospun wrap of polycaprolactone (PCL) + graphene oxide (GO), with and without xenogeneic human adipose tissue-derived MSCs (hADMSCs) to use as a platform for neural tissue engineering. Methods: We evaluated, in vitro and in vivo, the potential of the nerve wrap in providing support for axonal growth. To establish the rat sciatic nerve defect model, a 10 mm long limiting defect was created in the rat sciatic nerve of 18 Lewis rats. Rats treated with the nanocomposites were compared with autograft-treated defects. Gait, histological, and muscle analyses were performed after sacrifice at 12 weeks post-surgery. Results: Our findings demonstrate that hADMSCs had the potential to transdifferentiate into neural lineage and that the nanocomposite successfully delivered hADMSCs to the injury site. Histologically, we show that the PCL + GO nanocomposite with hADMSCs is comparable to the autologous nerve graft, to support and guide axonal growth. Conclusions: The novel PCL + GO nerve wrap and hADMSCs used in this study provide a foundation on which to build upon and generate future strategies for PNI repair.


  • Open Access

    Novel Kraft Softwood Lignin-Derived Carbon Quantum Dots: Synthesis, Characterization, and In Vitro Cytocompatibility

    by Eli Christoph, Lu Yu, Steven D. Newby, Michael A. Rivera Orsini, Jakob Scroggins, David J. Keffer, David P. Harper, Madhu Dhar

    Carbon quantum dots (CQDs) have been investigated for biomedical applications in medical imaging due to their fluorescent properties, overall long-term stability, and excellent cytocompatibility and biocompatibility. Lignin is an organic polymer in the tissues of woody plants. It is also considered a byproduct of the wood and pulp industries. Hence, it presents as a renewable source of carbon nanoparticles. In this study, we report the synthesis and material and biological characterization of two colloidal suspensions of CQDs in water derived from lignin-based carbon. One was the native form of CQDs derived from lignin carbon, and the second was doped with nitrogen to evaluate material differences. Material characterization was carried out using various commonly used techniques, including Fourier transform infrared spectroscopy (FTIR), emission and absorbance spectra, zeta potential, transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Thin films of CQDs were formed on glass and silicon substrates to assess the in vitro cytocompatibility with human mesenchymal stem cells (hMSCs). Observations suggest that the two forms of CQDs promote cell attachment within 24 h and sustain it for at least 7 days. The overall structure and shape of cells suggest a lack of any adverse or toxic effects of CQDs. The data lay down the novel foundation to support the use of lignin-derived CQDs in tissue engineering applications.